WO1998001558A3 - Protein and peptide vaccines for inducing mucosal immunity - Google Patents

Protein and peptide vaccines for inducing mucosal immunity Download PDF

Info

Publication number
WO1998001558A3
WO1998001558A3 PCT/US1997/012253 US9712253W WO9801558A3 WO 1998001558 A3 WO1998001558 A3 WO 1998001558A3 US 9712253 W US9712253 W US 9712253W WO 9801558 A3 WO9801558 A3 WO 9801558A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
transmitted diseases
mucosal immunity
peptide vaccines
inducing mucosal
Prior art date
Application number
PCT/US1997/012253
Other languages
French (fr)
Other versions
WO1998001558A2 (en
Inventor
George H Lowell
Thomas C Vancott
Deborah L Birx
Original Assignee
Intellivax Inc
Henry M Jackson Foundation
Us Army
George H Lowell
Thomas C Vancott
Deborah L Birx
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellivax Inc, Henry M Jackson Foundation, Us Army, George H Lowell, Thomas C Vancott, Deborah L Birx filed Critical Intellivax Inc
Priority to AU36629/97A priority Critical patent/AU739723B2/en
Priority to EP97933443A priority patent/EP0929678A2/en
Priority to JP50537298A priority patent/JP2001505535A/en
Publication of WO1998001558A2 publication Critical patent/WO1998001558A2/en
Publication of WO1998001558A3 publication Critical patent/WO1998001558A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A novel vaccine composition combines a protein or peptide antigen, optionally added hydrophobic material and an immunopotentiating membranous carrier which together preserve the antigenic integrity of the protein or peptide epitopes while at the same time enhancing their immunogenicity. Administration of this composition to a subject provokes a protective immune response comprising secretory neutralizing antibodies present in various mucosal sites in the body. This vaccine and the process for using it is intended for use against pathogenic organisms, in particular those causing sexually transmitted diseases or mucosally transmitted diseases. Such organisms include bacteria and enveloped viruses, particularly HIV-1.
PCT/US1997/012253 1996-07-10 1997-07-10 Protein and peptide vaccines for inducing mucosal immunity WO1998001558A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU36629/97A AU739723B2 (en) 1996-07-10 1997-07-10 Protein and peptide vaccines for inducing mucosal immunity
EP97933443A EP0929678A2 (en) 1996-07-10 1997-07-10 Protein and peptide vaccines for inducing mucosal immunity
JP50537298A JP2001505535A (en) 1996-07-10 1997-07-10 Protein and peptide vaccines for inducing mucosal immunity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2168796P 1996-07-10 1996-07-10
US60/021,687 1996-07-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09214701 A-371-Of-International 1999-09-30
US09/938,406 Division US20020155120A1 (en) 1996-07-10 2001-08-21 Protein and peptide vaccines for inducing mucosal immunity

Publications (2)

Publication Number Publication Date
WO1998001558A2 WO1998001558A2 (en) 1998-01-15
WO1998001558A3 true WO1998001558A3 (en) 1998-05-14

Family

ID=21805590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012253 WO1998001558A2 (en) 1996-07-10 1997-07-10 Protein and peptide vaccines for inducing mucosal immunity

Country Status (5)

Country Link
EP (1) EP0929678A2 (en)
JP (1) JP2001505535A (en)
AU (1) AU739723B2 (en)
CA (1) CA2259961A1 (en)
WO (1) WO1998001558A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
EP1721618A3 (en) * 2000-02-15 2007-01-10 ID Biomedical Corporation of Quebec Proteosome influenza vaccine composition
AU2001238478C1 (en) * 2000-02-15 2006-11-09 Id Biomedical Corporation Of Quebec Proteosome influenza vaccine
EP2198882A3 (en) * 2001-01-12 2010-10-13 Novartis Vaccines and Diagnostics, Inc. Nucleic acid mucosal immunization
JP4137640B2 (en) 2001-03-09 2008-08-20 アイディー バイオメディカル コーポレイション オブ ケベック Novel proteosome-liposaccharide vaccine adjuvant
US7255867B2 (en) 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
GB201520595D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
FRANKENBURG ET AL: "EFFECTIVE IMMUNIZATION OF MICE AGAINST CUTANEOUS LEISHMANIASIS USING AN INTRINSICALLY ADJUVANTED SYNTHETIC LIPOPEPTIDE VACCINE", VACCINE, vol. 14, no. 9, June 1996 (1996-06-01), pages 923 - 929, XP002055664 *
KAMINSKI ET AL: "HIV PEPTIDE AND PROTEIN ANTIBODY RESPONSES ELICITED BY IMMUNIZATION WITH RGP 160 FORMULATED WITH PROTEOSOMES, ALUM, AND/OR SUBMICRON EMULSIONS", VACCINE RESEARCH, vol. 4, 1995, pages 189 - 206, XP002055662 *
KAMINSKI ET AL: "PARENTERAL OR INTRANASAL IMMUNIZATION WITH HIV GP160 FORMULATED WITH PROTEOSOMES AND/OR PA ADJUVANTS ENHANCES EPITOPE-SPECIFIC IGG OR IGA", 94TH GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, 1994, pages 155, XP002055658 *
LEVI ET AL: "INTRANASAL IMMUNIZATION OF MICE AGAINST INFLUENZA WITH SYNTHETIC PEPTIDES ANCHORED TO PROTEOSOMES", VACCINE, vol. 13, no. 14, 1995, pages 1353 - 1359, XP002055656 *
LOWELL ET AL: "MUCOSAL IMMUNOGENICITY AND EFFICACY OF PROTEOSOMES AND PA ADJUVANTS FOR HIV, INFLUENZA, SHIGELLA AND STAPH. ENTEROTOXIN B (SEB) VACCINES", JOURNAL OF CELLULAR BIOCHEMISTRY, no. S19A, 1995, pages 259, XP002055657 *
LOWELL ET AL: "NASAL IMMUNIZATION WITH HIV GP160 FORMULATED WITH PROTEOSOMES, EMULSOMES AND/OR CHOLERA TOXIN B SUBUNIT: INDUCTION OF ANTI-GP160 SERUM IGA AND IGG AND INTESTINAL, VAGINAL AND LUNG IGA", AMERICAN SOCIETY FOR MICROLBIOLOGY. HUMAN RETROVIRUSES AND RELATED INFECTIONS. 2ND NATIONAL CONFERENCE, - 1995, pages 81, XP002055659 *
LOWELL ET AL: "PEPTIDES BOUND TO PROTEOSOMES VIA HYDROPHOBIC FEET BECOME HIGHLY IMMUNOGENIC WITHOUT ADJUVANTS", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 167, 1988, pages 658 - 663, XP002055660 *
LOWELL ET AL: "PROTEOSOME-LIPOPEPTIDE VACCINES: ENHANCEMENT OF IMMUNOGENICITY FOR MALARIA CS PEPTIDES", SCIENCE, vol. 240, 1988, pages 800 - 802, XP002055663 *
LOWELL ET AL: "PROTEOSOMES, EMULSOMES, AND CHOLERA TOXIN B IMPROVE NASAL IMMUNOGENICITY OF HUMAN IMMUNODEFICIENCY VIRUS GP160 IN MICE: INDUCTION OF SERUM, INTESTINAL, VAGINAL, AND LUNG IGA AND IGG", THE JOURNAL OF INFECTIOUS DISEASES, vol. 175, no. 2, February 1997 (1997-02-01), pages 292 - 301, XP002055661 *
VANCOTT ET AL: "CHARACTERIZATION OF A SOLUBLE, OLIGOMERIC HIV-1 GP160 PROTEIN AS A POTENTIAL IMMUNOGEN", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 183, 1995, pages 103 - 117, XP002055665 *
YANG ET AL: "THE HUMAN AND SIMIAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEIN TRANSMEMBRANE SUBUNITS ARE PALMITOYLATED", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 92, 1995, pages 9871 - 9875, XP002055666 *

Also Published As

Publication number Publication date
AU3662997A (en) 1998-02-02
CA2259961A1 (en) 1998-01-15
AU739723B2 (en) 2001-10-18
EP0929678A2 (en) 1999-07-21
WO1998001558A2 (en) 1998-01-15
JP2001505535A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
Hu et al. Immunostimulating complexes (ISCOMs) for nasal vaccination
Morein et al. Current status and potential application of ISCOMs in veterinary medicine
Kurar et al. Nucleic acid vaccination of Brucella abortus ribosomal L7L12 gene elicits immune response
AU2015265884B2 (en) Vaccine composition against Streptococcus suis infection
EP0245078A3 (en) Enhancement of antigen immunogenicity
ES2141750T5 (en) COMPOSITION THAT CONTAINS AT A TIME A SOLUBLE FORM AND AN INSOLUBLE FORM OF AN IMMUNOGEN.
PL392964A1 (en) Hyperimmune serum reactive antigen, the use of this antigen for the production of a pharmaceutical formulation, fragment of the hiperimmune antigen, antigen auxiliary epitopes, a vaccine containing the hyperimmune serum reactive antigen, formulation containing antibodies, process for the preparation of this formulation, the use of the formulation for the treatment of staphylococcal infections, and screening method
RU2000116260A (en) LTB ADJUVANT VACCINES
Hamajima et al. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response
WO1989002277A3 (en) Prophylaxis and therapy of acquired immunodeficiency syndrome
Nyika et al. DNA vaccination with map1 gene followed by protein boost augments protection against challenge with Cowdria ruminantium, the agent of heartwater
WO1998001558A3 (en) Protein and peptide vaccines for inducing mucosal immunity
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
Hinkula et al. Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses
McCLUSKIE et al. Immunization against hepatitis B virus by mucosal administration of antigen–antibody complexes
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
MX9801089A (en) Hybrid protein comprising t-helper cell stimulating epitopes and b-cell epitopes from the major outer membrane protein of chlamydia trachomatis and its use as a vaccine.
Morein Iscoms
Toussaint et al. Prime-boost strategies combining DNA and inactivated vaccines confer high immunity and protection in cattle against bovine herpesvirus-1
Wang et al. Immunogenicity of a bovine viral diarrhea virus E2–C3d fusion protein containing a bovine homolog of C3d
EP1490100B1 (en) Combined dna/protein vaccine compositions
EA200200931A1 (en) SYSTEM FOR DELIVERY OF THE VACCINE THROUGH THE MUDDY SHELL OF URINARY OR ANORECTAL TRACT
WO2005021574A3 (en) Induction of antiviral neutralizing antibodies in humans and animals
NZ528055A (en) Immunogenic liposome compositions comprising vesicle forming lipids and an antigenic construct and methods of inducing an immune response using them
AU2667600A (en) Identification of specific differentially expressed antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

ENP Entry into the national phase

Ref document number: 2259961

Country of ref document: CA

Ref country code: CA

Ref document number: 2259961

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 505372

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997933443

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997933443

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09214701

Country of ref document: US

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI9711099

Country of ref document: BR

Kind code of ref document: A2

Free format text: PEDIDO CONSIDERADO RETIRADO EM RELACAO AO BRASIL E ARQUIVADO POR NAO ATENDER O DISPOSTO NOS ITENS 9.2 E 9.2.1 DO ATO NORMATIVO NO 128/1997 DE 05/03/1997 E POR NAO TER CUMPRIDO EXIGENCIA PUBLICADA NA RPI NO 1873 DE 28/11/2006.